Last updated: March 2026
Clenbuterol is a β2-adrenergic receptor agonist — NOT an anabolic steroid — used for thermogenic fat loss and muscle preservation during cutting phases. Originally a bronchodilator, it is approved for veterinary use and human asthma treatment in some countries, but is NOT FDA-approved for human use in the United States. Cardiac hypertrophy is the primary long-term risk.
Clenbuterol's effects are mediated entirely through β2-adrenergic receptor activation — NOT androgen receptors. It increases metabolic rate, promotes lipolysis, and has anti-catabolic effects through a completely different pathway than anabolic steroids.
Clenbuterol selectively binds β2-adrenergic receptors in adipose tissue, skeletal muscle, and the cardiovascular system. This binding increases intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA), triggering a cascade that upregulates metabolic rate and core body temperature. The result is increased energy expenditure at rest — typically estimated at 5-10% elevation in basal metabolic rate at moderate doses. This thermogenic effect is the primary driver of fat loss.
β2 receptor activation in skeletal muscle triggers anabolic signaling pathways (including mTOR activation) that help preserve lean tissue during caloric deficit. This anti-catabolic effect is why clenbuterol is popular in cutting phases — it helps spare muscle while fat is lost. Animal studies show significant muscle-preserving effects, though human data is more limited. This is NOT the same mechanism as anabolic steroids; clenbuterol does not bind androgen receptors.
Chronic β2 receptor stimulation causes receptor downregulation — the body reduces receptor density in response to constant activation. This leads to tolerance, with effects diminishing after 2-3 weeks of continuous use. Two protocols are commonly used: (1) 2-weeks on / 2-weeks off cycling to allow receptor upregulation, or (2) continuous use with ketotifen, an antihistamine that upregulates β2 receptors and can extend clenbuterol effectiveness. Without cycling or ketotifen, thermogenic effects attenuate significantly.
β2 receptors are abundant in cardiac tissue. Clenbuterol's cardiac stimulation increases heart rate (tachycardia), elevates blood pressure, and — with chronic use — can cause pathological cardiac hypertrophy (enlargement of heart muscle in a pattern associated with dysfunction). Animal studies show clear cardiac fibrosis and hypertrophy with prolonged use. This is the most serious long-term risk and the primary reason duration and dose must be limited.
Clenbuterol has more human research than most compounds on this site due to its medical applications. However, studies at performance enhancement doses are limited. Animal data provides the clearest mechanistic picture.
Cardiovascular monitoring and electrolyte support are the primary harm-reduction priorities for clenbuterol use.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and harm-reduction purposes only. Clenbuterol is NOT approved by the FDA for human use in the United States. It is approved for veterinary/equine use and for human asthma treatment in some other countries. In the US, it is sometimes obtained through gray-market or research chemical sources, which carries legal and quality-control risks. Chronic use has been associated with cardiac hypertrophy in animal studies and human case reports. This content does not constitute medical advice. Always consult a licensed physician before using any performance-enhancing substance.